Perspective Therapeutics (NYSE:CATX) Stock Price Up 4.9% – Should You Buy?

Perspective Therapeutics, Inc. (NYSE:CATX) shares rose 4.9% on Tuesday . The stock traded as high as $12.89 and last traded at $12.89. Approximately 269,258 shares were traded during mid-day trading, a decline of 61% from the average daily volume of 683,831 shares. The stock had previously closed at $12.29.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on CATX shares. Truist Financial assumed coverage on shares of Perspective Therapeutics in a research report on Wednesday, September 25th. They set a “buy” rating and a $21.00 target price for the company. Bank of America started coverage on shares of Perspective Therapeutics in a report on Thursday, July 25th. They set a “buy” rating and a $24.00 price objective for the company. Wedbush initiated coverage on Perspective Therapeutics in a research report on Tuesday, October 1st. They set an “outperform” rating and a $25.00 price target on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Perspective Therapeutics in a research report on Monday, September 9th. Finally, Royal Bank of Canada reduced their price objective on Perspective Therapeutics from $29.00 to $27.00 and set an “outperform” rating on the stock in a research note on Friday, August 16th. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $21.43.

Perspective Therapeutics Stock Up 1.9 %

The company’s 50 day simple moving average is $13.83.

Perspective Therapeutics (NYSE:CATX) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.17) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.04. The firm had revenue of $0.53 million during the quarter. On average, equities research analysts anticipate that Perspective Therapeutics, Inc. will post -0.87 EPS for the current year.

Institutional Trading of Perspective Therapeutics

Institutional investors have recently bought and sold shares of the business. Victory Capital Management Inc. bought a new position in Perspective Therapeutics during the 2nd quarter worth approximately $117,000. Point72 DIFC Ltd bought a new position in shares of Perspective Therapeutics during the second quarter worth $118,000. SG Americas Securities LLC acquired a new position in shares of Perspective Therapeutics in the 3rd quarter valued at $246,000. The Manufacturers Life Insurance Company bought a new stake in shares of Perspective Therapeutics in the 2nd quarter valued at $188,000. Finally, Iowa State Bank acquired a new stake in Perspective Therapeutics during the 3rd quarter worth $254,000. Institutional investors and hedge funds own 54.66% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.